NIZATIDINE IN THE TREATMENT OF REFLUX ESOPHAGITIS - AN ITALIAN MULTICENTER STUDY

被引：4

作者：

BALDI, F

LONGANESI, A

FERRARINI, F

MORSELLILABATE, AM

VOI, M

CAMARRI, F

PORRO, GB

TITTOBELLO, A

DOBRILLA, G

ANGELINI, G

CELLE, G

MAZZEO, F

BEDOGNI, V

MATTIOLI, S

ANGELETTI, CA

CORAZZIARI, E

CIPOLLETTA, L

SABBATINI, F

FAMILIARI, F

FERRAU, O

PUSTORINO, S

LICATA, A

RUSSO, A

机构：

[1] Department of Internal Medicine and Gastroenterology, Policlinico S. Orsola, Bologna

[2] Medical Department of Eli Lilly Italia, Sesto Fiorentino

来源：

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 1993年 / 5卷 / 06期

关键词：

EROSIVE ESOPHAGITIS; MEDICAL TREATMENT; SYMPTOMATIC RELIEF; NIZATIDINE; ENDOSCOPIC HEALING;

D O I：

10.1097/00042737-199306000-00015

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

objective: To evaluate the various doses and administration schedules of nizatidine in the treatment of reflux oesophagitis. Design and methods: Two hundred and forty patients with erosive-ulcerative oesophagitis were randomly allocated to a 6-week treatment regimen with nizatidine 150 mg three times daily (group A, n = 79), 150 + 150 + 300 mg (group B, n = 79) and 300 mg twice daily (group C, n = 82). Clinical evaluation was performed at entry and after 3 and 6 weeks, whereas endoscopy and laboratory tests were performed only at entry and at the end of the study. Results: Reflux symptoms were significantly reduced in all three groups after 6 weeks. The patients on three times daily regimens (groups A and B) improved some of their symptoms faster than those in group C. Oesophagitis healed with similar frequency in the three groups (A = 81.1%, B = 79.2% and C = 67.6%). Adverse events were rare and mild. Conclusions: High-dose nizatidine is safe and effective in relieving the symptoms and healing the lesions of oesophagitis.

引用

页码：475 / 478

页数：4

共 13 条

[1] Klinkenberg-Knol E.C., Recent advances in the management of gastroesophageal reflux disease, Scand J Gastroenterol, 26, pp. 101-107, (1991)
[2] Naccarato R., Cremer M., Damman H.G., Keohane P.P., Mulder H., Sarles H., Et al., Nizatidine versus ranitidine in gastric ulcer disease, Scand J Gastroenterol, 22, pp. 71-78, (1987)
[3] Simon B., Cremer M., Damman H.G., Hentschel E., Mueller P., Sarles H., Et al., 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer: A multicentre study in Europe, Scand J Gastroenterol, 22, pp. 61-70, (1987)
[4] Koelz H.R., Birchler R., Bretiiolz A., Bros B., Caitraink Y., Delmore G., Healing and relapse of reflux esophagitis during treatment with ranitidine, Gastroenterology, 91, pp. 1198-1205, (1986)
[5] Lethola J., Niemkla S., Martikainen J., Krekela I., Ranitidine, 150mg three times a day, in the treatment of reflux esophagitis. A placebo-controlled, double blind study, Scand J Gastroenterol, 21, pp. 175-180, (1986)
[6] Pace F., Sangaletti O., Bianchi Porro G., Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis, Ital J Gastroenterol, 22, pp. 28-32, (1990)
[7] Berges W., Lux G., Simon B., Wienbeck M., Qrik R., A comparison of two doses of nizatidine in reflux oesophagitis [abstract]. Z, Gastroenterol, 3, (1989)
[8] Quik R., Cooper M.J., Gleeson M., Hentschel E., Schuetze K.S., Kingston R.D., Et al., A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis, Aliment Pharmacol Therap, 4, pp. 201-211, (1990)
[9] Cloud M., Offen W.W., Robinson M., Nizatidine versus placebo in gastroesophageal reflux disease: A 12-week, multicenter, randomized, double-blind study, Am J Gastroenterol, 86, pp. 1735-1742, (1991)
[10] Siegel S., Nonparametric Statistics for the Behavioral Sciences, (1956)

← 1 2 →